Evaluation and Medical Management of Thyroid Cancer

  • Margaret M. Petersen
  • I. Ross McDougall
Part of the Cancer Treatment and Research book series (CTAR, volume 52)

Abstract

Thyroid cancer is the most common endocrine cancer, yet there are only about 12,100 new cases per year in the U.S. with 1,100 deaths annually. In contrast, clinically significant thyroid nodules are found in 5% of the population and of those evaluated, about 10% have been shown to be malignant. This has been demonstrated by several studies using fine needle aspiration (FNA) which has been found to be more accurate than ultrasound or scintigraphy in predicing malignancy in thyroid nodules. The above figures suggest that the risk of death from a malignant thyroid nodule is very low. Thyroid cancer generally has a good prognosis, particularly in the 70–90% of patients (in the U.S.) who have well-differentiated cancers. There are now numerous retrospective studies on significant numbers of patients who have been followed for a sufficient length of time to enable important conclusions to be drawn regarding management and therapy [1–4]. Major controversies still exist regarding both the extent of surgical resection of the thyroid following diagnosis and the role of radioiodine therapy. There are a small number of patients with aggressive forms of thyroid cancer in whom the prognosis is bleak and the survival rate so low that clinicians have been unable to follow them long enough to judge whether treatments are influencing outcome.

Keywords

Adenoma Aspirin Oncol Radionuclide Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mazzaferri EL: Papillary thyroid carcinoma: Factors influencing prognosis and current therapy. Semin Oncol 14:315–332, 1987.PubMedGoogle Scholar
  2. 2.
    Tubiana M, Schlumberger M, Rougier P, et al.: Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794–804, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    McConahey WM, Hay ID, Wollner LB, et al.: Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy and outcome. Mayo Clin Proc 61:978–996, 1987.Google Scholar
  4. 4.
    Rossi RL, Nieroda C, Cady B, et al.: Malignancies of the thyroid gland. The Lahey Clinic experience. Surg Clin N Am 65:211–230, 1985.PubMedGoogle Scholar
  5. 5.
    Werner SC: Classification of thyroid disease. Report of the committee on nomenclature the American Thyroid Association—Part I. J Clin Endocrinol Metab 29:860–862, 1969.PubMedCrossRefGoogle Scholar
  6. 6.
    Duffy BJ Jr, Fitzgerald PJ: Cancer of the thyroid in children: A report of 28 cases. J Clin Endocrinol Metab 10:1296–1308, 1950.PubMedCrossRefGoogle Scholar
  7. 7.
    Favus MJ, Schneider AB, Stachura ME, et al.: Thyroid cancer occurring as a late consequence of head-and-neck irradiation: Evaluation of 1056 patients. N Engl J Med 294:1019–1025, 1976.PubMedCrossRefGoogle Scholar
  8. 8.
    DeGroot L, Paloyan E: Thyroid carcinoma and radiation: A Chicago endemic. JAMA 225:487–491, 1973.PubMedCrossRefGoogle Scholar
  9. 9.
    Clark OH, Greenspan FS, Dunphy JE: Hashimoto’s thyroiditis and thyroid cancer: Indications for operation. Am J Surg 140:65–70, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Black BM, Kirk TA, Woolner LB: Multicentricity of papillary adenocarcinoma of the thyroid: Influence on treatment. J Clin Endocrinol Metab 20:130–135, 1960.PubMedCrossRefGoogle Scholar
  11. 11.
    Carcangiu ML, Zampi G, Pupi A, et al.: Papillary carcinoma of the thyroid: A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805–828, 1985.PubMedCrossRefGoogle Scholar
  12. 12.
    Staunton MD, Skeet RG: Thyroid cancer: Prognosis in 469 patients. Br J Surg 66:643–647, 1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Simpson WJ, McKinney SE, Carruthers JS, et al.: Papillary and follicular thyroid cancer: Prognostic factors in 1,578 patients. Am J Med 83:479–488, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Heitz P, Mosher H, Staub JJ: Thyroid cancer: A study of 573 thyroid tumors and 161 autopsy cases observed over a thirty-year period. Cancer 37:2329–2337, 1976.PubMedCrossRefGoogle Scholar
  15. 15.
    Clark RL Jr, White EC, Russel WO: Total thyroidectomy for cancer of the thyroid: Significance of intraglandular dissemination. Ann Surg 149:858–866, 1959.PubMedCrossRefGoogle Scholar
  16. 16.
    Clark OH: Total thyroidectomy: The treatment of choice for patients with differentiated thyroid cancer. Ann Surg 196:361–370, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Jacobs JK, Aland JW, Ballinger JR, et al.: Total thyroidectomy: A review of 213 patients. Ann Surg 197:542–548, 1983.PubMedCrossRefGoogle Scholar
  18. 18.
    Attie JN, Moskowitz GW, Margouleff D, et al.: Feasibility of total thyroidectomy in the treatment of thyroid carcinoma: Postoperative radioactive iodine evaluation in 140 cases. Am J Surg 138:555–560, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Harness JK, Fung L, Thompson NW, et al.: Total thyroidectomy: Complications and technique. World J Surg 10:781–786, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Mazzaferri EL, Young RL, Oertel JE, et al.: Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine 56:171–195, 1977.PubMedCrossRefGoogle Scholar
  21. 21.
    Rossi RL, Cady B, Silverman ML, et al.: Current results of conservation surgery for differentiated thyroid carcinoma. World J Surg 10:612–622, 1986.PubMedCrossRefGoogle Scholar
  22. 22.
    Starnes HF, Brooks DC, Pinkus GS, et al.: Surgery for thyroid carcinoma. Cancer 55:1376–1381, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Hay ID, Grant CS, Taylor WF, et al.: Ipsilateral lobectormy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095, 1987.PubMedGoogle Scholar
  24. 24.
    Sako K, Marchetta FC, Razack MS, et al.: Modified radical neck dissection for metastatic carcinoma of the thyroid: a reappraisal. Am J Surg 150:500–502, 1985.PubMedCrossRefGoogle Scholar
  25. 25.
    Mazzaferri EL, Young RL: Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518, 1981.PubMedCrossRefGoogle Scholar
  26. 26.
    Crile G Jr, Antunez AR, Esselstyn CB, et al.: The advantages of subtotal thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid. Cancer 55:2691–2697, 1985.PubMedCrossRefGoogle Scholar
  27. 27.
    Hilts SV, Hellman D, Anderson J, et al.: Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma. J Nucl Med 20:928–932, 1979.PubMedGoogle Scholar
  28. 28.
    Beckerman C, Gottschalk A, Hoffer PB: Optimal time for 131I total body imaging to detect metastatic thyroid carcinoma. J Nucl Med 15:477, Abst 1974.Google Scholar
  29. 29.
    McCowen KD, Adler RA, Ghaed N, et al.: Low dose radioiodine thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 61:52–58, 1976.PubMedCrossRefGoogle Scholar
  30. 30.
    Ryo UY: Low-dose and high-dose radioiodine in thyroid cancer. Am J Med 61:52–58, 1976.CrossRefGoogle Scholar
  31. 31.
    Kuni CC, Klingensmith WC: Failure of low doses 131I to ablate residual thyroid tissue following surgery for thyroid cancer. Radiology 137:773–774, 1980.PubMedGoogle Scholar
  32. 32.
    Siddiqui AR, Edmonson J, Wellman HH, et al.: Feasibility of low doses of 131I for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 6:158–161, 1981.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramacciotti C, Pretorius HT, Line BR, et al.: Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: concise communication. J Nucl Med 23:483–489, 1982.PubMedGoogle Scholar
  34. 34.
    DeGroot LJ, Reilly M: Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 96:51–53, 1982.PubMedGoogle Scholar
  35. 35.
    Snyder J, Gorman C, Scanlon P: Thyroid remnant ablation: Questionable pursuit of an ill-defined goal. J Nucl Med 24:659–665, 1983.PubMedGoogle Scholar
  36. 36.
    Maxon HR, Thomas SR, Hertzberg VS, et al.: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937–941, 1983.PubMedCrossRefGoogle Scholar
  37. 37.
    Freebberg AS, Ureles AL, Lesses MF, et al.: Pulmonary metastatic lesion successfully treated with radioactive iodine. JAMA 144:16–19, 1950.Google Scholar
  38. 38.
    Turner JE, Weir G J Jr: Pulmonary metastases from thyroid carcinoma detectable only by 131I scan. Treatment and response. J Nucl Med 13:854–855, 1972.Google Scholar
  39. 39.
    Massin JP, Savoie JC, Gamier H, et al.: Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 53:982–992, 1984.PubMedCrossRefGoogle Scholar
  40. 40.
    Samaan NA, Schultz PN, Haynie TP, et al.: Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 65:376–380, 1985.CrossRefGoogle Scholar
  41. 41.
    Rall JE, Alpers JB, Lewallen CG, et al.: Radiation pneumonitis and fibrosis: A complication of radioiodine treatment of plumonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 17:1263–1276, 1957.PubMedCrossRefGoogle Scholar
  42. 42.
    Castillo LA, Yeh SDJ, Leeper RD, et al.: Bone scan in bone metastases from functioning thyroid carcinoma. Clin Nucl Med 5:200–209, 1980.PubMedCrossRefGoogle Scholar
  43. 43.
    Holmquest D1, Lake P: Sudden hemorrhage in metastatic carcinoma of the brain during treatment with iodine-131. J Nucl Med 17:307–309, 1976.PubMedGoogle Scholar
  44. 44.
    Datz FL: Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 27:637–640, 1986.PubMedGoogle Scholar
  45. 45.
    Goldberg LD, Ditchek NT: Thyroid carcinoma with spinal cord compression. JAMA 245:953, 1981.PubMedCrossRefGoogle Scholar
  46. 46.
    Shortliffe EH, Crapo LM: Thyroid carcinoma with spinal cord compression. JAMA 247:2566–1567, 1982.CrossRefGoogle Scholar
  47. 47.
    Nemec J, Rohling S, Zamrazil V, et al.: Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 20:92–97, 1979.PubMedGoogle Scholar
  48. 48.
    Allweiss P, Braunstein GD, Katz A, et al.: Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med 25:755–758, 1984.PubMedGoogle Scholar
  49. 49.
    Pochin EE: Long term hazards of radioiodine treatment of thyroid carcinoma. UICC Monograph Series Vol 12 Thyroid Cancer. Hedinger C (ed) Berlin: Springer-Verlag P293–304, 1969.Google Scholar
  50. 50.
    Edmonds CJ, Smith T: The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45–51, 1986.PubMedCrossRefGoogle Scholar
  51. 51.
    Sarkar SD, Beierwaltes WH, Gill SP, et al.: Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17:460–464, 1976.PubMedGoogle Scholar
  52. 52.
    Ahmed SR, Shalet SM: Gonadal damage due to radioactive iodine (I131) treatment for thyroid carcinoma. Postgrad Med J 61:361–362, 1985.PubMedCrossRefGoogle Scholar
  53. 53.
    National Council on Radiation Protection and Measurements. Report No. 37. Precautions in the management of patients who have received therapeutic amounts of radionuclides, 1970.Google Scholar
  54. 54.
    Brendel AJ, Guyot M, LeFort G, et al.: Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 29:1515–1520, 1988.PubMedGoogle Scholar
  55. 55.
    Van Herle AJ, Uller RP: Elevated serum thyroglobulin: A marker of metastases in differentiated thyroid carcinomas. J Clin Invest 56:272–277, 1975.PubMedCrossRefGoogle Scholar
  56. 56.
    Shlossberg AH, Jacobson JCJ, Ibbertson HK: Serum thyroglobulin in the diagnosis and management of thyroid carcinoma. Clin Endocrinol 10:17–27, 1979.CrossRefGoogle Scholar
  57. 57.
    Blahd WH, Drickman MV, Porter CW, et al.: Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: concise communication. J Nucl Med 25:673–676, 1984.PubMedGoogle Scholar
  58. 58.
    McDougall IR, Bayer MF: Follow-up of patients with differentiated thyroid cancer using serum thyroglobulin measured by an immunoradiometric assay. Comparison with I-131 total body scans. J Nucl Med 21:741–744, 1980.PubMedGoogle Scholar
  59. 59.
    Bayer MF, McDougall IR, Kriss JP: Retrospective study of serum thyroglobulin measurements performed in patients with differentiated thyroid carcinoma at the Stanford University thyroid clinic between 1979 and 1985. In: Thyroglobulin and thyroglobulin antibodies in the follow-up of thyroid cancer and endemic goiter M Hufner and C Reiners (ed) Georg Thieme Verlang Stuttgart, pp 104–111, 1987.Google Scholar
  60. 60.
    Miller JH, Marcus CS: Metastatic papillary thyroid carcinoma with normal serum thyroglobulin level. Clin Nucl Med 13:652–653, 1988.PubMedCrossRefGoogle Scholar
  61. 61.
    Hay ID, Grant CS, Taylor WF, et al.: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma. A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095, 1987.PubMedGoogle Scholar
  62. 62.
    Cady B, Sedgwick CE, Meissner WA, et al.: Risk factor analysis in differentiated thyroid cancer. Cancer 43:810–820, 1979.PubMedCrossRefGoogle Scholar
  63. 63.
    Harwood J, Clark OH, Dunphy JE: Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 136:107–112, 1978.PubMedCrossRefGoogle Scholar
  64. 64.
    Leeper RD: The effect of 131I therapy on survival of patients with metastatic papillary or follicular thyroid cancer. J Clin Endocrinol 36:1143–1152, 1973.CrossRefGoogle Scholar
  65. 65.
    Varma VM, Beierwalte WH, Nofal MM, et al.: Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodide I 131. JAMA 214:1437–1442, 1970.PubMedCrossRefGoogle Scholar
  66. 66.
    Leeper RD: Thyroid Cancer. Med Clin N Am 69:1079–1096, 1985.PubMedGoogle Scholar
  67. 67.
    Beierwaltes WH: The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79–94, 1978.PubMedCrossRefGoogle Scholar
  68. 68.
    Krishnamurthy GT, Blahd WH: Radioiodine I-131 therapy in the management of thyroid carcinoma: a prospective study. Cancer 40:195–202, 1977.PubMedCrossRefGoogle Scholar
  69. 69.
    LiVolsi VA: Pathology of thyroid cancer. In: Thyroid Cancer, Greenfield LD (ed). West Palm Beach: CRC Press, pp 85–141, 1978.Google Scholar
  70. 70.
    Ober KP, Cowan FR, Sevier RE, et al.: Thyrotoxicosis caused by functioning metastatic thyroid carcinoma. Clin Nucl Med 12:345–348, 1987.PubMedCrossRefGoogle Scholar
  71. 71.
    Pont A, Spratt D, Shinn JB: T3 toxicosis due to nonmetastatic follicular carcinoma of the thyroid. West J Med 136:255–258, 1982.PubMedGoogle Scholar
  72. 72.
    Harness JK, Thomson NW, McLeod MK, et al.: Follicular carcinoma of the thyroid gland: Trends and treatment. Surgery 96:972–978, 1984.PubMedGoogle Scholar
  73. 73.
    Lang W, Choritz H, Hundeshagen H: Risk factors in follicular thyroid carcinomas. Am J Surg Pthol 10:246–255, 1986.CrossRefGoogle Scholar
  74. 74.
    Young RL, Mazzaferri EL, Rahe AJ, et al.: Pure follicular thyroid carcinoma: Impact of therapy on 214 patients. J Nucl Med 21:733–739, 1980.PubMedGoogle Scholar
  75. 75.
    Watson RG, Brennan MD, Goellner JR, et al.: Invasive Hurthle cell carcinoma of the thyroid: Natural history and management. Mayo Clin Proc 59:851–855, 1984.PubMedGoogle Scholar
  76. 76.
    Fisher ER, Kim WS: Primary clear cell thyroid carcinoma with squamous features. Cancer 39:2497–2502, 1977.PubMedCrossRefGoogle Scholar
  77. 77.
    Jaques DA, Chambers RG, Oertel JE: Thyroglossal tract carcinoma. A review of the literature and addition of eighteen cases. Am J Surg 1230:439–446, 1970.CrossRefGoogle Scholar
  78. 78.
    Joseph TJ, Komorowski RA: Thyroglossal duct carcinoma. Hum Pathol 6:717–729, 1975.PubMedCrossRefGoogle Scholar
  79. 79.
    Roses DR, Snively SL, Cohen N, et al.: Carcinoma of the thyroglossal duct. Am J Surg 145:266–269, 1983.PubMedCrossRefGoogle Scholar
  80. 80.
    Pardo-Mindan FJ, Vazquez JJ: Malignant struma ovarii: Light and electron microscopic study. Cancer 51:337–343, 1983.PubMedCrossRefGoogle Scholar
  81. 81.
    Kempers RD, Dockerty MB, Hoffman DL, et al.: Struma ovarii-Ascitic, hyperthyroid, and asymptomatic syndromes. Ann Intern Med 72:883–893, 1970.PubMedGoogle Scholar
  82. 82.
    McDougall IR, Krasne D, Hanberry JW, et al.: Malignant Struma ovarii presenting as paraparesis from a spinal metastasis. J Nucl Med 30:407–411, 1989.PubMedGoogle Scholar
  83. 83.
    Aldinger KA, Samaan NA, Ibanez M, et al.: Anaplastic carcinoma of the thyroid. A review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 41:2267–2275, 1978.PubMedCrossRefGoogle Scholar
  84. 84.
    Kapp DS, Li Volsi VA, Sanders MM: Anaplastic carcinoma following well-differentiated thyroid carcinoma: etilogical considerations. Yale J Biol Med 55:521–528, 1982.PubMedGoogle Scholar
  85. 85.
    Carcangiu ML, Steeper T, Zampi G, et al.: Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathl 83:135–158, 1985.Google Scholar
  86. 86.
    Shevro J, Gal R, Avidor I, et al.: Anaplastic thyroid carcinoma. A clinical, histologic and immunochemical study. Cancer 62:319–325, 1984.CrossRefGoogle Scholar
  87. 87.
    Casterline PF, Jaques DA, Blom H, et al.: Anaplastic giant and spindle-cell carcinoma of the thyroid. Cancer 45:1689–1692, 1980.PubMedCrossRefGoogle Scholar
  88. 88.
    Kim JH, Leeper RD: Treatment of anaplastic giant and spindle cell carcinoma of the thyroid with combination Adriamycin and radiation therapy. A new approach. Cancer 52:954–957, 1983.PubMedCrossRefGoogle Scholar
  89. 89.
    Spanos GA, Wolk D, Desner MR, et al.: Preoperative chemotherapy for giant cell carcinoma of the thyroid. Cancer 50:2252–2256, 1982.PubMedCrossRefGoogle Scholar
  90. 90.
    Glotzman D, Pott JT Jr, Ridge way EC, et al.: Calcitonin as a tumor marker: User of a radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma. N Engl J Med 290:1035–1039, 1974.CrossRefGoogle Scholar
  91. 91.
    Rougier P, Calmettes C, Laplanche A, et al.: The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer 51:855–862, 1983.PubMedCrossRefGoogle Scholar
  92. 92.
    Tashjian AH Jr, Howland BG, Melvin KEW, et al.: Immunoassay of human calcitonin: Clinical measurement, relation to serum calcium and studies in patients with medullary carcinoma. N Engl J Med 283:890–895, 1970.CrossRefGoogle Scholar
  93. 93.
    Pont A: Multiple endocrine neoplasic syndromes. West J Med 132:301–312, 1980.PubMedGoogle Scholar
  94. 94.
    Sizemore GW: Medullary cancer of the thyroid gland. Semi Oncol 14:306–314, 1987.Google Scholar
  95. 95.
    Williams ED: Medullary carcinoma and other disorders involving calcitonin. In: Endocrinology Volume 2, DeGroot LJ, et al. (ed). New York: Grune and Stratton, pp 777–792, 1981.Google Scholar
  96. 96.
    Sizemore GW, Go VLM: Stimulation tests for diagnosis of medullary thyroid carcinoma. Mayo Clin Proc 50:53–56, 1975.PubMedGoogle Scholar
  97. 97.
    Wells SA, Dilley WG, Farndon JA, et al.: Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med 145:1248–1252, 1985.PubMedCrossRefGoogle Scholar
  98. 98.
    Hoefnagel CA, Delprat CC, Zanin D, et al.: New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159–165, 1988.PubMedCrossRefGoogle Scholar
  99. 99.
    Sisson JC, Frager MS, Valk TW, et al.: Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12–17, 1981.PubMedCrossRefGoogle Scholar
  100. 100.
    Sisson JC, Shapiro B, Beierwaltes WH, et al.: Radiopharmaceutical treatment of maligant pheochromocytoma. J Nucl Med 24:197–206, 1984.Google Scholar
  101. 101.
    Miyauchi A, Endo K, Ohta H, et al.: 99mTc(v) Dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma. World J Surg 10:640–645, 1986.PubMedCrossRefGoogle Scholar
  102. 102.
    Guilloteau D, Baulieu JL, Besnard JC: Medullary-thyroid-carcinoma imaging in an animal model: Use of radiolabeled anticalcitonin F(ab)2 and metaiodobenzylguanidine. Eur J Nucl Med 11:198–200, 1985.PubMedCrossRefGoogle Scholar
  103. 103.
    Hellman DE, Kartchner M, Van Antiwerp JD, et al.: Radioiodine in the treatment of medullary carcinoma of the thyroid, J Clin Endocrinol Metab 48:451–455, 1979.PubMedCrossRefGoogle Scholar
  104. 104.
    Deftos LJ, Stein MF: Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50:967–968, 1980.PubMedCrossRefGoogle Scholar
  105. 105.
    Saad MF, Ordonez NG, Rashid RK, et al.: Medullary carcinoma of the thyroid: A study of the clinical features and prognostic factors in 161 patients. Medicine 63:319–341, 1984.PubMedCrossRefGoogle Scholar
  106. 106.
    Hamburger JI, Miller JM, Kini Sr: Lymphoma of the thyroid. Ann Intern Med 99:685–693, 1983.PubMedGoogle Scholar
  107. 107.
    Rappaport H: Tumors of the Hematopoietic System. Atlas of Tumor Pathology, Fascicle 8, Section 3. Armed Forces Institute of Pathology, 1964.Google Scholar
  108. 108.
    Chak LY, Hoppe RT, Burke JS, et al.: Non-Hodgkin’s lymphoma presenting as thyroid enlargement. Cancer 48:2712–2716, 1981.PubMedCrossRefGoogle Scholar
  109. 109.
    Burke JS, Butler JJ, Fuller LM: Malignant lymphomas of the thyroid. A clinical pathologic study of 35 patients including ultrastructure observations. Cancer 39:1587–1602, 1977.PubMedCrossRefGoogle Scholar
  110. 110.
    Devine RM, Edis AJ, Banks DM: Primary lymphoma of the thyroid: A review of the Mayo Clinic experience. World J Surg 5:33–38, 1981.PubMedCrossRefGoogle Scholar
  111. 111.
    Grimley RP, Oates GD: The natural history of malignant thyroid lymphomas. Br J Surg 67:475–477, 1980.PubMedCrossRefGoogle Scholar
  112. 112.
    Maurer R, Taylor CR, Terry R, et al.: Non-Hodgkin’s lymphoma of the thyroid gland. Birch Arch A Path Anat Histol 383:293–319, 1979.CrossRefGoogle Scholar
  113. 113.
    Schwarze EW, Papadimitriou CS: Non-Hodgkin’s lymphoma of the thyroid. Path Res Pract 167:346–362, 1980.PubMedGoogle Scholar
  114. 114.
    Sirota DK, Segal RL: Primary lymphomas of the thyroid gland. JAMA 242:1743–1746, 1979.PubMedCrossRefGoogle Scholar
  115. 115.
    Souhami L, Simpson J, Carrurthers JS: Malignant lymphoma of the thyroid gland. Int J Rad One Biol Phys 6:1143–1147, 1980.CrossRefGoogle Scholar
  116. 116.
    Holm LE, Blomgren, Lowhagen T: Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312:601–604, 1985.PubMedCrossRefGoogle Scholar
  117. 117.
    Shimaoka K, Van Herle AJ, Dindogru A: Thyrotoxicosis secondary to involvement of the thyroid with malignant lymphoma. J Clin Endocrinol Metab 43:64–68, 1976.PubMedCrossRefGoogle Scholar
  118. 118.
    McCabe DP, Farrar WB, Petkov TM, et al.: Clinical and pathologic correlation in disease metastatic to the thyroid. Am J Surg 150:519–523, 1985.PubMedCrossRefGoogle Scholar
  119. 119.
    Ivy HK: Cancer metastatic to the thyroid: A diagnostic problem. Mayo Clin Proc 59:856–859, 1984.PubMedGoogle Scholar
  120. 120.
    Watts NB: Carcinoma metastatic to the thyroid: prevalence and diagnosis by fine needle aspiration cytology. Am J Med Sci 293:13–17, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Margaret M. Petersen
  • I. Ross McDougall

There are no affiliations available

Personalised recommendations